Xentuzumab
Xentuzumab is a monoclonal antibody that has been developed for the treatment of various types of cancer. It specifically targets the insulin-like growth factor 1 receptor (IGF-1R), which plays a crucial role in the growth and survival of cancer cells.
Mechanism of Action[edit | edit source]
Xentuzumab is designed to bind to the IGF-1R, a receptor that is often overexpressed in cancer cells. By binding to this receptor, xentuzumab inhibits the signaling pathways that promote cell proliferation and survival. This can lead to reduced tumor growth and potentially enhance the effectiveness of other cancer therapies.
Clinical Development[edit | edit source]
Xentuzumab has been evaluated in several clinical trials to assess its safety and efficacy in treating different types of cancer, including breast cancer, lung cancer, and prostate cancer.
Breast Cancer[edit | edit source]
In studies involving patients with hormone receptor-positive breast cancer, xentuzumab has been tested in combination with other therapies such as endocrine therapy. The results have shown promise in terms of slowing disease progression.
Lung Cancer[edit | edit source]
For patients with non-small cell lung cancer (NSCLC), xentuzumab has been investigated as a potential treatment option, particularly in cases where the cancer has become resistant to other forms of therapy.
Prostate Cancer[edit | edit source]
Xentuzumab has also been studied in the context of castration-resistant prostate cancer, where it is used in combination with other agents to improve patient outcomes.
Side Effects[edit | edit source]
As with many monoclonal antibodies, xentuzumab can cause a range of side effects. Common side effects include fatigue, nausea, and infusion-related reactions. More serious side effects may include immune-related adverse events and increased risk of infections.
Regulatory Status[edit | edit source]
As of the latest updates, xentuzumab is still undergoing clinical trials and has not yet received approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Research and Future Directions[edit | edit source]
Ongoing research is focused on understanding the full potential of xentuzumab in combination with other cancer therapies. Researchers are also investigating biomarkers that may predict which patients are most likely to benefit from treatment with xentuzumab.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Cancer immunotherapy
- Insulin-like growth factor 1 receptor
- Clinical trial
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
